Bookmark

Add to MyYahoo RSS

EXACT Sciences News

News on EXACT Sciences (Ticker: EXAS) continually updated from thousands of sources around the net.

Thursday Jul 24 | Business Wire

Doyle, Arora elected; Sterling reelected to Exact Sciencesa board of directors

Lionel N. Sterling has served as a director of Exact since 2010 and was reelected to the board.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Jim Doyle, US Governors, Dane County, WI, University of Wisconsin Madison, Non-Profit, Third Wave Technologies

Wed Jul 23, 2014

Seeking Alpha

Amidst Ongoing Doubts, Exact Sciences Still Offers Opportunity

Exact Sciences continues to wait for two critical gating events - FDA approval of the Cologuard test and CMS reimbursement for the test.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law, Marketing

AmericanBankingNews.com

EXACT Sciences Price Target Raised to $19.00 at Canaccord Genuity

The firm currently has a "buy" rating on the stock. Canaccord Genuity's price target suggests a potential upside of 15.22% from the company's current price.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Jul 22, 2014

Seeking Alpha

EXACT Sciences' (EXAS) CEO Kevin Conroy on Q2 2014 Results - Earnings Call Transcript

Good day, ladies and gentlemen, welcome to the Exact Sciences Second Quarter 2014 Earnings Conference Call.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Sales

Forbes.com

Use Options For a Chance To Buy EXAS at a 47% Discount

Corp. priced a 10,000,000 share secondary stock offering at $12.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Tuesday, the stock is now 28.2% above the offering price.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, 10,000,000, EightyEight Games LTD, Video Games, Financial Markets

Hispanic Business

Exact Sciences Reports Second-Quarter 2014 Financial Results

The company's revenue had been comprised of the non-cash amortization of up-front license fee payments paid to it by Genzyme Corp. These payments were amortized over a five-year collaboration period that ended in during the same period of 2013.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Sales, Colorectal Health, Health, Corporate / Securities Law, Law

Wed Jul 16, 2014

Freshnews

Exact Sciences to host second-quarter 2014 results, annual meeting webcasts and calls

Exact Sciences Corp. today announced that the company will host webcasts and conference calls to discuss its second-quarter 2014 financial results and of its annual meeting of stockholders.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Colorectal Health, Health, Corporate / Securities Law, Law

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••